MA53562A - Polythérapie destinée au traitement d'une maladie hépatique - Google Patents

Polythérapie destinée au traitement d'une maladie hépatique

Info

Publication number
MA53562A
MA53562A MA053562A MA53562A MA53562A MA 53562 A MA53562 A MA 53562A MA 053562 A MA053562 A MA 053562A MA 53562 A MA53562 A MA 53562A MA 53562 A MA53562 A MA 53562A
Authority
MA
Morocco
Prior art keywords
polytherapy
treatment
hepatic disease
hepatic
disease
Prior art date
Application number
MA053562A
Other languages
English (en)
Inventor
Allen Baharaff
Tali Gorfine
Liat Hayardeny-Nissimov
Original Assignee
Galmed Res And Development Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galmed Res And Development Ltd filed Critical Galmed Res And Development Ltd
Publication of MA53562A publication Critical patent/MA53562A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/662Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/665Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Botany (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA053562A 2018-09-06 2019-09-03 Polythérapie destinée au traitement d'une maladie hépatique MA53562A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862727565P 2018-09-06 2018-09-06

Publications (1)

Publication Number Publication Date
MA53562A true MA53562A (fr) 2021-07-14

Family

ID=69722275

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053562A MA53562A (fr) 2018-09-06 2019-09-03 Polythérapie destinée au traitement d'une maladie hépatique

Country Status (12)

Country Link
US (1) US12239712B2 (fr)
EP (1) EP3846821B1 (fr)
JP (1) JP2022500366A (fr)
KR (1) KR102876077B1 (fr)
CN (1) CN113164498A (fr)
AU (1) AU2019334939B2 (fr)
BR (1) BR112021004140A2 (fr)
CA (1) CA3111025C (fr)
IL (1) IL281244B2 (fr)
MA (1) MA53562A (fr)
MX (1) MX2021002655A (fr)
WO (1) WO2020049556A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111909137B (zh) * 2019-05-10 2023-05-30 深圳微芯生物科技股份有限公司 一种哒嗪酮衍生物及其应用
WO2021204751A1 (fr) * 2020-04-06 2021-10-14 Poxel Combinaison pharmaceutique pour le traitement de maladies du foie
CN113698388B (zh) * 2020-05-20 2022-11-22 江苏恒瑞医药股份有限公司 6-氧代-1,6-二氢吡啶类衍生物、其制备方法及其在医药上的应用
CN114437034A (zh) * 2020-11-06 2022-05-06 深圳微芯生物科技股份有限公司 一种酞嗪类化合物的可药用盐、晶型及其制备方法
CN114685450A (zh) * 2020-12-30 2022-07-01 昆药集团股份有限公司 2-吡啶酮类衍生物及其制备方法和在医药上的应用
WO2024211898A1 (fr) 2023-04-07 2024-10-10 Terns Pharmaceuticals, Inc. Association comprenant un agoniste thrbeta anda glp-1r destiné à être utilisé dans le traitement d'un trouble du foie ou d'une maladie cardiométabolique
CN121443313A (zh) * 2023-06-08 2026-01-30 成都微芯药业有限公司 PPAR全激动剂联合THR-β激动剂在抗代谢相关疾病中的用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2614529C (fr) * 2005-07-21 2011-06-28 F. Hoffmann-La Roche Ag Derives de pyridazinone utilises comme agonistes du recepteur de l'hormone thyroidienne
CA2972919A1 (fr) * 2015-01-09 2016-07-14 Gilead Apollo, Llc Therapie combinee a base d'un inhibiteur de l'acc utilisable en vue du traitement de la steatose hepatique non alcoolique
ES2924257T3 (es) * 2016-10-18 2022-10-05 Madrigal Pharmaceuticals Inc Métodos de tratar trastornos hepáticos o trastornos lipídicos con un agonista de THR-beta
US11197870B2 (en) * 2016-11-10 2021-12-14 Galmed Research And Development Ltd Treatment for hepatic fibrosis

Also Published As

Publication number Publication date
IL281244B2 (en) 2025-05-01
AU2019334939B2 (en) 2025-03-27
CA3111025C (fr) 2023-10-31
KR102876077B1 (ko) 2025-10-23
CA3111025A1 (fr) 2020-03-12
BR112021004140A2 (pt) 2021-05-25
EP3846821A1 (fr) 2021-07-14
KR20210057758A (ko) 2021-05-21
WO2020049556A1 (fr) 2020-03-12
EP3846821A4 (fr) 2022-05-25
IL281244A (en) 2021-04-29
US20210338826A1 (en) 2021-11-04
AU2019334939A1 (en) 2021-04-29
US12239712B2 (en) 2025-03-04
IL281244B1 (en) 2025-01-01
MX2021002655A (es) 2021-05-27
JP2022500366A (ja) 2022-01-04
EP3846821B1 (fr) 2023-10-04
CN113164498A (zh) 2021-07-23

Similar Documents

Publication Publication Date Title
EP3846821A4 (fr) Polythérapie destinée au traitement d'une maladie hépatique
MA54229A (fr) Composés et compositions destinés au traitement d'états pathologiques associés à une activité de nlrp
EP3880823A4 (fr) Virus adéno-associé thérapeutique pour le traitement de la maladie de pompe
IL271046A (en) Compounds for treating huntington's disease
EP3790867A4 (fr) Inhibiteurs de kdm1a pour le traitement d'une maladie
EP3950686A4 (fr) Dérivés d'amide n-hétéroaromatiques destinés au traitement du cancer
EP3675859A4 (fr) Composés, compositions et méthodes pour le traitement d'une maladie
MA44864A (fr) Trithérapie pour le traitement d'une maladie intestinale inflammatoire
MA49906A (fr) Acides aminés à chaîne ramifiée pour le traitement d'une maladie du foie
EP3558313A4 (fr) Substances pour le traitement d'affections liées à la stéatose hépatique
EP3718561A4 (fr) Agent thérapeutique pour une maladie inflammatoire de l'intestin
EP3737361A4 (fr) Inhibiteurs de la dihydrocéramide désaturase pour le traitement d'une maladie
EP3405215A4 (fr) Méthodes destinées au traitement de la maladie de danon et d'autres troubles liés à l'autophagie
EP3419622A4 (fr) Traitement d'une maladie neurodégénérative de l'oeil à l'aide de pridopidine
EP3405183A4 (fr) Dérivés d'adamatane pour le traitement d'une infection à filovirus
EP3630102A4 (fr) Formulations pour le traitement d'un trouble de stress post-traumatique
MA49131A (fr) Utilisation d'antagonistes de klk5 pour le traitement d'une maladie
MA55199A (fr) Leucine, acétyl leucine et analogues apparentés pour le traitement d'une maladie
EP3504204A4 (fr) Indazolyl-l,2,4-thiadiazolamines et composés apparentés pour l'inhibition de protéine kinase associée à rho et le traitement de la maladie
EP3440094A4 (fr) Inhibiteur de la localisation mitochondriale de tdp -43 pour le traitement d'une maladie neurodégénérative
EP3773221A4 (fr) Traitement pour l'hydrocéphalie
EP3796980A4 (fr) Thérapie génique pour la maladie d'alzheimer
MA54522A (fr) Composition pharmaceutique pour le traitement de l'hypertension artérielle pulmonaire
EP3781695A4 (fr) Importation d'arn mitochondrial pour le traitement d'une maladie mitochondriale
EP3638252A4 (fr) Activateurs dépendant de sting pour le traitement d'une maladie